Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:
the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
the company provides dupilumab according to the commercial arrangement.
Stop dupilumab at 16 weeks if the atopic dermatitis has not responded adequately. An adequate response is:
at least a 50% reduction in the Eczema Area and Severity Index score (EASI 50) from when treatment started and
at least a 4‑point reduction in the Dermatology Life Quality Index (DLQI) from when treatment started